Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHASE

Exclusion Criteria29

• rTMS exposure for treatment or research purposes in the last 6 months.
• History of seizure, epilepsy, syncope, fainting episode, or head trauma resulting in loss of consciousness.
• Presence or history of neurological disorders (migraine, stroke, Alzheimer's Disease and other Dementias, Parkinson's Disease, Multiple Sclerosis, Traumatic Brain Injury (TBI), increased intracranial pressure).
• History of brain surgery, implanted electronic device, metal in the head.
• Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps or sensors, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes)
• History of or currently under medical care for myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke, or transient ischemic attack.
• Reports vision problems that are not treated.
• Has a hairstyle not compatible with the EEG and unwilling to modify hairstyle (e.g., braids, ponytails, dreadlocks, non-removable hair extensions or wigs, etc.) to accommodate the EGG net that is required to be worn on the scalp during the experimental procedure.
• Reports current diagnosis or history of type I diabetes.
• Currently using insulin.
• Have undergone bariatric surgery.
• Currently being enrolled in a weight loss program.
• Takes any prescription or over the counter medications or supplements to control weight and/or appetite.
• Self-report a history of or current diagnosis of a mental health condition.
• Reports insomnia (<4 hours sleep per night, in 3 or more nights per week in the last 3 months)
• Reports <4 hours of sleep the day of the visit
• Reports using marijuana on a daily basis.
• Reports having used any other illicit drugs (other than marijuana) or prescription medications for non-medical reasons in the last 12 months.
• Currently receiving treatment for substance use disorder (e.g., alcohol, opioids, cocaine, marijuana, or stimulants).
• Females who report averaging more than 7 alcoholic drinks, or males who report averaging more than 14 alcoholic drinks in a single week in the last 30 days.
• Current use of certain medications (last 3 months):
• Investigational drugs. Drugs of anti or pro-convulsive action. Medications with psychotropic effects (e.g., antidepressants, antipsychotics).
• Medications known to increase risk of seizure Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix). Nicotine replacement therapy with the intent to quit smoking (e.g., patches, gum, lozenge, pouches, etc).
• Being pregnant or lactating
• Self-reported noise-induced hearing loss or tinnitus.
• Currently participating in any other research study.
• Any otherwise not specified medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and/or Study Physician.
• \. Any otherwise not specified medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and/or Study Physician.
• \. Subjects considered by the investigator as unsuitable for the study for reasons not otherwise stated.